FOLFOX-HAIC in combination with lenvatinib and PD-1 inhibitor demonstrated a promising antitumor activity with manageable safety profiles in patients with advanced iCCA. The gene discussed is PDCD1; the disease is infantile convulsions and choreoathetosis.